- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06800313
En studie av HLD-0915 hos patienter med metastaserande kastreringsresistent prostatacancer (MCRPC)
Fas 1/2 studie av HLD-0915 hos patienter med metastaserande kastreringsresistent prostatacancer (MCRPC)
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Study Contact
- Telefonnummer: 844-434-4210
- E-post: Participate-In-This-Study1@its.jnj.com
Studieorter
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80909
- Rekrytering
- Rocky Mountain Cancer Center
-
Denver, Colorado, Förenta staterna, 80218
- Rekrytering
- Sarah Cannon Research Institute 1
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06511
- Rekrytering
- Yale University
-
-
Florida
-
Sarasota, Florida, Förenta staterna, 34232
- Rekrytering
- Florida Cancer Specialists
-
-
Louisiana
-
Metairie, Louisiana, Förenta staterna, 70006
- Rekrytering
- XCancer Research Network LCMC Health EJGH
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Rekrytering
- Dana Farber Mass General Brigham Cancer Care Inc
-
-
Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49546
- Rekrytering
- South Texas Accelerated Research Therapeutics, LLC (START)
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68130
- Rekrytering
- Urology Cancer Center, PC
-
-
New York
-
Long Island City, New York, Förenta staterna, 11101
- Rekrytering
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Förenta staterna, 13210
- Rekrytering
- Associated Medical Professionals
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27710
- Rekrytering
- Duke University Medical Center
-
-
South Carolina
-
Myrtle Beach, South Carolina, Förenta staterna, 29572
- Rekrytering
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Förenta staterna, 37209
- Rekrytering
- Urology Associates
-
-
Texas
-
Austin, Texas, Förenta staterna, 78758
- Rekrytering
- NEXT Oncology
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- MD Anderson Cancer Center
-
-
Virginia
-
Norfolk, Virginia, Förenta staterna, 23502
- Rekrytering
- Virginia Clinical Research
-
-
-
-
-
Sutton, Storbritannien, SM2 5PT
- Rekrytering
- The Royal Marsden NHS Trust
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Patients must meet the following criteria to be eligible study participation:
Key Inclusion Criteria:
All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication
mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen
SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI
mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL
Key Exclusion Criteria:
All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):
Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition
mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods
SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer
mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: JNJ-101556143 Phase 1 Part 1 - Dose Escalation
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimentell: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 Experimental: Oral JNJ-101556143 |
|
Experimentell: JNJ-101556143 Phase 2 Part 1 - Dose Optimization
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimentell: Phase 2 Part 2A - SOAR
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimentell: Phase 2 Part 2B - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimentell: Phase 2 Part 2C - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
|
Experimentell: Phase 2 Part 2D - HSPC Expansion
Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) |
Experimental: Oral JNJ-101556143 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Frequency of dose-limiting toxicities (DLTs)
Tidsram: 21 days
|
21 days
|
|
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Tidsram: 21 days
|
21 days
|
|
Phase 1 Part 2 (formulation exploration) relative bioavailability
Tidsram: 22 days
|
22 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
PK Parameters
Tidsram: 21 days
|
21 days
|
|
|
Duration of Response (DOR)
Tidsram: 21 days
|
21 days
|
|
|
Radiographic Progression-Free Survival (rPFS)
Tidsram: 63 days
|
63 days
|
|
|
Time to Response (TTR)
Tidsram: 63 days
|
63 days
|
|
|
Change in PSA over time
Tidsram: 21 days
|
Including PSA50 and PSA90 response |
21 days
|
|
Objective Response Rate (ORR)
Tidsram: 63 days
|
Per RECIST in evaluable patients |
63 days
|
Samarbetspartners och utredare
Utredare
- Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- Prostatacancer
- Prostata Adenocarcinom
- Prostatiska neoplasmer
- Genitala neoplasmer, manliga
- Neoplasmer, körtel och epitel
- Genitala sjukdomar, manliga
- Metastaserad kastratresistent prostatacancer
- Urogenitala sjukdomar, manliga
- Ripta
- HLD-0915
- Urogenital Neoplasms, Male
- Hormone Sensitive, Castrate Resistant
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Neoplasmer efter plats
- Neoplasmer
- Prostatasjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Neoplasmer efter histologisk typ
- Prostatiska neoplasmer
- Neoplasmer, körtel och epitel
- Urogenitala neoplasmer
- Genitala neoplasmer, manliga
- Manliga urogenitala sjukdomar
- Genitala sjukdomar, manliga
Andra studie-ID-nummer
- HLD-0915-ONC-101
- HLD-0915-ONC-101 (Annan identifierare: Janssen Research & Development, LLC)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .